Neuro-oncology Advances
Overview
Neuro-oncology Advances is a scientific journal, published by Oxford University Press since 2019 in English. The journal's country of origin is United Kingdom.
Details
Details
Abbr.
Neurooncol Adv
Publisher
Oxford University Press
Start
2019
End
Continuing
e-ISSN
2632-2498
Country
United Kingdom
Language
English
Metrics
Metrics
h-index / Ranks: 11173
26
SJR / Ranks: 2424
1315
CiteScore / Ranks: 6351
4.20
Recent Articles
1.
Friedrich M, Werner J, Steinbach J, Sabel M, Herrlinger U, Piroth M, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf023.
PMID: 40084168
Background: Amino acid PET using the tracer -(2-[F]fluoroethyl)-l-tyrosine (FET) is one of the most reliable imaging methods for detecting glioma recurrence. Here, we hypothesized that functional MR connectivity between the...
2.
Lin T, Kuo C, Chang F, Lin S, Chen Y, Liang M, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf020.
PMID: 40051663
Background: Chemotherapy plays an important role in the treatment of optic pathway hypothalamic gliomas (OPHGs). Commonly used regimens include carboplatin and vincristine and monotherapy with vinblastine weekly. In this retrospective...
3.
Derks S, Ho L, Koene S, Starmans M, Oomen-de Hoop E, Joosse A, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf026.
PMID: 40051662
Background: Immune checkpoint inhibitors (ICIs) are effective treatments for patients with metastatic melanoma, including patients with brain metastasis (BM). However, half of patients with melanoma BM have intracranial progression within...
4.
Ellingson B, Okobi Q, Chong R, Plawat R, Zhao E, Gafita A, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf022.
PMID: 40051661
Background: To demonstrate the potential value of F-fluorodeoxyglucose positron emission tomography (F-FDG PET) as a rapid, non-invasive metabolic imaging surrogate for pharmacological modulation of EGFR signaling in EGFR-driven GBM, we...
5.
Mohammad A, Sakalla R, Davalan W, Ruiz-Barerra M, Jatana S, Khalaf R, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf014.
PMID: 40051660
Background: Neutrophil-to-lymphocyte ratio (NLR) is used in the prognostication of multiple malignancies. However, the NLR value in glioblastoma (GBM) is controversial. This controversy may be due to the unaccounted effect...
6.
van Schie P, Huisman R, Wiersma T, Knegjens J, Jansen E, Brandsma D, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf027.
PMID: 40051659
Background: Novel systemic therapies, such as immunotherapy and targeted therapies, have shown better systemic disease control in the last decennium. However, the effect of these treatments on distant brain failure...
7.
Rodriguez Almaraz E, Guerra G, Al-Adli N, Young J, Dada A, Quintana D, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf024.
PMID: 40051658
Background: Isocitrate dehydrogenase (IDH)-mutant astrocytomas represent the most frequent primary intraparenchymal brain tumor in young adults, which typically arise as low-grade neoplasms that often progress and transform to higher grade...
8.
Darlix A, Bady P, Deverdun J, Lefort K, Rigau V, Le Bars E, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdae224.
PMID: 40041202
Background: Diffuse IDH mutant low-grade gliomas (IDHmt LGG) (World Health Organization grade 2) typically affect young adults. The outcome is variable, with survival ranging from 5 to over 20 years....
9.
Slattery K, Kauss M, Raval D, Hsieh E, Choi A, Davis T, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf002.
PMID: 40041201
Background: Cognitive dysfunction is common among patients with malignant glioma, yet the underlying mechanisms of this dysfunction remain unclear. Protein markers of neurodegeneration, inflammation, and vascular damage have been associated...
10.
Neurooncol Adv
. 2025 Feb;
7(1):vdae213.
PMID: 39991183
[This corrects the article DOI: 10.1093/noajnl/vdae165.].